Клозапин. ЗАКЛЮЧЕНИЕ

Клозапин

Последние сообщения указывают, что для мак­симально эффективного лечения клозапином больных с явлениями терапевтической резис-тентности необходим уровень концентрации препарата в плазме крови от 350 до 450 нг/мл [14, 47-49].

ЗАКЛЮЧЕНИЕ

В заключение необходимо отметить, что роль мониторинга уровня концентрации препарата в плазме крови все еще остается очень неопре­деленной. Тем не менее лекарственный мони­торинг может быть полезен в следующих ситу­ациях:

• Для определения правильности выполнения больным терапевтического режима.

• Для установления адекватности назначений у больных с устойчивостью к терапии.

• Для предотвращения токсического действия излишне высокого уровня концентрации пре­парата в плазме крови.

• Для наблюдения за состоянием больных с сопутствующими соматическими заболева­ниями или с дополнительными психотроп-ными или другими лекарственными назна­чениями.

• Для получения максимальной клинической реакции в тех случаях, когда связь между уровнем концентрации препарата и клини­ческой реакцией четко установлена.

• Для получения данных, которые могут быть использованы с целью установить взаимоот­ношения между дозировкой препарата и клинической реакцией на него.

• Для подстраховки врача в потенциально сложных медико-правовых ситуациях.

литература

1. Wode-Helgodt В, Borg S, Fyro В, Sedvall G. Cli­nical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 1978; 58: 149-173-

2. Chang SS, Javaid JI, Dysken MW, Casper RC, Jani-cak PG, Davis JM. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology 1985; 87: 55-58.

3. Dysken MW, Javaid JI, Chang SS, Schaffer C, Sha-hid A, Davis JM. Fluphenazine pharmacokine-tics and therapeutic response. Psychopharmaco­logy 1981; 73: 205-210.

4. Janicak PC. Javaid JI, Sharma RP, ComatyJE, Pe-terson J, Davis JM. Trifluoperazine plasma levels and clinical response. J Clin Psychopharmacol 1989; 9 (5): 340-346.

5. Mavroidis ML, Kanter DR, Hirschowitz J, Carver DL Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol 1984; 4 (3): 155-157.

6. Smith RC, Baumgartner R, Misra CH, et al. Halo-peridol. Plasma levels and prolactin response as predictors of clinical improvement in schizo­phrenia. Chemical versus radioreceptor plasma level assays. Arch Gen Psychiatry 1984; 41: 1044-1049,

7. Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 1984; 4: 133-137.

8. Mavroidis ML, Garver L Plasma haloperidol le­vels and clinical response: confounding variables. Psychopharmacol Bull 1985; 21: 62-65.

9. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R. Does a therapeutic window for plasma haloperidol exist? Preliminary Chine­se data. Psychopharmacol Bull 1985; 21 (1): 59-61.

10. Van Putten T, Marder SR, May PRA, Poland RE, O'Brien RP. Plasma levels of haloperidol and cli­nical response. Psychopharmacol Bull 1985; 21: 69-72.

11. Van Putten T, Marder SR, Mintz J, Poland RE. Ha­loperidol plasma levels and clinical response: a therapeutic window relationship. Psychophar­macol Bull 1988; 24: 172-175.

12. Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R. Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 1985; 21: 48-51.

13. Santos JL, Cabranes JA, Vasquez FF, Almoguera I, Ramos JA. Clinical response and plasma haloperi­dol levels in chronic and subchronic schizophre­nia. Biol Psychiatry 1989; 26: 381-388.

14. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Cloza-pine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenia. Am J Psychiatry 1991; 148: 231-235.

 15. Marder S, Davis JM, Janicak PG, eds. Clinical use of neuroleptic plasma levels. Washington, DC: American Psychiatric Press, Inc, 1993; 137-142.

16. Curry SH. Determination of nanogram quantities of chlorpromazine or its metabolites in plasma using gas liquid chromatography with an electron capture detector. Anal Chem 1968; 40: 1251-1255.

17. Curry SH, Marshall JHL, Davis JM, Janowsky DS. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 1970; 22: 289-296.

18. May PRA, Van Putten T, Jenden DJ, Yale C, Dixon WJ. Chlor-promazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 1981; 38: 202-207.

19. Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N. Plasma fluphenazine lev­els and clinical response in newly admitted schi­zophrenic patients. Psychopharmacol Bull 1991; 27 (2): 91-96.

20. Marder SR, Van Putten T, Aravagiri M, et al. Flu­phenazine plasma levels and clinical response. Psychopharmacol Bull 1990; 26: 256-259.

21. Yesavage JA, Holman CA, Cohn R, Lombrozo L Correlation of initial serum levels and clinical response. Arch Gen Psychiatry 1983; 40: 301-304.

22. Janicak PG, Javaid JI, Davis JM. Neuroleptic plas­ma levels: methodological issues, study design, and clinical applicability. In: Marder SR, Davis JM, Janicak PG, eds. Clinical use of neuroleptic plasma levels. Washington, DC: APPI Press, 1993: 17-44.

23. Smith RC. Plasma haloperidol levels and clinical response. Arch Gen Psychiatry 1987; 44: 1110-1112.

24. Palao DJ, Arauxo A, Brunei M, et al. Haloperidol: therapeutic window in schizophrenia. J Clin Psy-chopharmacology 1994; 14: 303-310.

25. Magliozzi JR, Hollister LE, Arnold KV, Earle GM. Relationship of serum haloperidol levels to clini­cal response in schizophrenic patients. Am J Psy­chiatry 1981; 138 (3): 365-367.

26. Bleeker JAC, Dingemans PM, Frohne-de Winter ML, van der Slooten EPJ. Plasma level and effect of low dose haloperidol in acute psychosis. Psy­chopharmacol Bull 1984; 20 (2): 317-319-

27. Shostak M, Perel JM, Steller RL, et al. Plasma ha­loperidol and clinical response: a role for reduced haloperidol in antipsychotic activity. J Clin Psy­chopharmacol 1987; 7: 394-400.

28. Doddi S, Rifkin A, Karajgi B, Cooper T, Borenstein M. Blood levels of haloperidol and clinical outcome in schizophrenia. J Clin Psychopharmacol 1994; 14 (3): 187-195.

29. Kirch GG, Bigelow LB, Korpi ER, Wagner RL, Zalc-man S, Wyatt RJ. Serum haloperidol concentra­tion and clinical response in schizophrenia. Schi­zophrenia Bull 1988; 14 (2): 283-289.

30. Bigelow L, Kirch DG, Braun T, et al. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenics: a fixed-dose study. Psychopharmacol Bull 1985; 21 (1): 66-68.

31. Rimon R, Averbuch I, Rozick P, et al. Serum and CSF levels of haloperidol by radioirnmunoassay and radioreceptor assay during high-dose thera­py of resistant schizophrenic patients. Psycho-pharmacology 1981; 73: 197-199.

32. Coryell W, Kelly M, Perry P, Miller DD. Haloperi­dol plasma levels and acute clinical change in schizophrenia. J Clin Psychoparmacol 1990; 10 (6): 397-402.

33. Volavka J, Cooper ТВ. Review of haloperidol level and clinical response: looking through the window. J Clin Psychopharmacol 1987; 7: 25-30.

34. Perry PJ, Pfohl BM, Kelly MW. The relationship of haloperidol concentrations to therapeutic res­ponse. J Clin Psychopharmacol 1988; 8: 38-43.

35. Volavka J, Cooper T, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psy­chiatry 1992; 49: 354-361.

36. Volavka J, Cooper ТВ, Czobor P, Meisner M. Plas­ma haloperidol levels and clinical effects in schi-zoprenia and schizoaffective disorder. Arch Gen Psychiatry 1995; 52: 837-845.

37. Janicak PG, Javaid JI, Sharma RP, et al. A two-phase, double-blind randomized study of three haloperidol blood levels for acute psychosis with reassignment of initial non-responders. Acta Psy-chiatrica Scand 1997; 95: 343-350.

38. Javaid JI, Janicak PG, Hedeker D, Sharma RP, Da-vis JM. Steady-state plasma level prediction for haloperidol from a single test dose. Psychophar­macol Bull 1991; 27 (1): 83-88.

39. Javaid JI, Janicak PG, Sharma RP, Leach A, Davis JM, Wang Z. Prediction of haloperidol steady-state levels in plasma after a single test dose. J Clin Psychopharmacology 1996; 16: 45-50.

40. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A control­led study of the neuroleptic threshold and high­er haloperidol dose. Arch Gen Psychiatry 1991; 48: 739-745.

41. Nordstrom Α -L, Farde L, Halldin С. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 1993; 110: 365-367.

42. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperi-done. Psychopharmacology 1993; 110: 265-272.

43. Wolkin A, Brodie JD, Barouche F, et al. Dopamine receptor occupancy and haloperidol plasma levels [Letter]. Arch Gen Psychiary 1989; 46: 482-483.

44. Kapur S, Remington G, Jones C, et al. What is the lowest effective dose of haloperidol? Evidence from PET Studies. Biol Psychiatry 1996; 39: 513.

45. Ericksen SE, Hunt SW, Davis JM. Dosage of an-tipsychotic drugs [Letter]. New Engl J Med 1979; 294: 1296-1297.

46. Keck PE, Harrison GP, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic ma­lignant syndrome. A case study. Arch Gen Psychi­atry 1989; 46: 914-918.

47. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical res­ponse in treatment resistant schizophrenia. J Clin Psychiatry 1994; 55 [9, suppl B]: 117-121.

48. Miller DD, Fleming F, Holman TL, Perry PJ. Plas­ma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psy­chiatry 1994; 55 [9, suppl B]: 117-121.

49. Kronig MH, Munne RA, Szymanski S, et al. Plas­ma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am J Psychiatry 1995; 152: 179-182.

 

⇐ Предыдущая83848586878889909192Следующая ⇒

Поделиться:

Воспользуйтесь поиском по сайту: